Gold prices higher, remain near record highs on rate cut bets
President and COO of United Therapeutics (NASDAQ:UTHR), Michael Benkowitz, sold a total of $9.3 million in common stock on September 2, 2025. The sales occurred at prices ranging from $405.5949 to $419.63 per share. The $17.7 billion market cap company, which maintains impressive gross profit margins of 89%, has seen its stock surge over 27% in the past week.
According to a Form 4 filing with the Securities and Exchange Commission, the sales involved a total of 15,305 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. According to InvestingPro, United Therapeutics maintains an EXCELLENT financial health score, with strong profitability metrics and robust cash flow generation.
On the same day, Benkowitz also exercised stock options, acquiring 14,625 shares of United Therapeutics common stock at an exercise price of $135.42, for a total value of $3130503. These shares are held in a trust.
The filing also indicates that on September 1, Benkowitz exercised options to acquire 7,875 shares at $146.03 per share.
In other recent news, United Therapeutics has been in the spotlight following the announcement of successful results from its Phase 3 TETON-2 trial for Tyvaso, a treatment for idiopathic pulmonary fibrosis (IPF). The trial met its primary efficacy endpoint, demonstrating a significant improvement in forced vital capacity (FVC) compared to placebo. This positive outcome has led UBS to raise its price target for the company from $415 to $560, maintaining a Buy rating. Similarly, Jefferies increased its price target to $564, also maintaining a Buy rating, after noting the clinically meaningful improvements in the Tyvaso study.
Additionally, United Therapeutics has expanded its partnership with MannKind Corporation to develop a second dry powder inhalation therapy, building on their collaboration that produced Tyvaso DPI. This development follows the FDA approval of Tyvaso DPI for pulmonary hypertension in May 2022. Analysts from UBS continue to hold a positive outlook on United Therapeutics, highlighting the promising prospects of Tyvaso despite previous challenges in other disease states. These developments have collectively contributed to a surge in investor interest and stock activity for United Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.